Boao Lecheng International Medical Tourism Pilot Zone in Hainan, China, is one of the only places in the world where international patients can legally access stem cell therapy for Type 2 diabetes under clinical supervision. This guide covers how the treatment works, who qualifies, what it costs, and how to access it through China Care Health Tours — with full coordination from consultation to discharge.
Key Facts
- Stem cell therapy for diabetes at Boao Lecheng costs $15,000—$35,000 USD, compared to $40,000—$80,000 in Switzerland/Germany and is not commercially available in the United States.
- A Phase II clinical trial in China found approximately 60% of treated patients reduced their diabetes medication dosage at 12-month follow-up, with 15—20% achieving insulin independence.
- A 2021 systematic review in Stem Cell Reviews and Reports found MSC infusion produced average HbA1c reductions of 1.2—2.1% across multiple randomized trials.
- The treatment program at Boao Lecheng runs 7—14 days, with stem cells administered via 2—4 intravenous infusion sessions spaced over several days.
- Boao Lecheng is China’s only location where this therapy is available: the same MSC protocol is not legally accessible at standard clinical facilities in Beijing or Shanghai without full NMPA approval.
Table of Contents
What Is Stem Cell Therapy for Diabetes?
Type 2 diabetes affects over 537 million adults worldwide. Conventional treatment manages symptoms — it does not repair the underlying cellular damage. Stem cell therapy takes a fundamentally different approach: it targets the biological mechanisms driving insulin resistance and beta-cell dysfunction, with the goal of partial or full metabolic restoration.
The core mechanism involves mesenchymal stem cells (MSCs) — typically derived from umbilical cord tissue or the patient’s own bone marrow — which are administered intravenously or via targeted infusion. Once introduced, MSCs exert several therapeutic effects:
- Anti-inflammatory action: MSCs suppress the chronic low-grade inflammation that drives insulin resistance in Type 2 diabetes
- Beta-cell protection and regeneration: MSCs secrete growth factors that support the survival and regeneration of insulin-producing beta cells in the pancreas
- Immune modulation: In cases where autoimmunity is a contributing factor, MSCs recalibrate the immune response that damages pancreatic tissue
- Improved insulin sensitivity: Clinical observations consistently show improved HbA1c levels and reduced insulin dependence in treated patients
This is not an experimental concept. Multiple published clinical trials have demonstrated measurable improvements in glycemic control following MSC infusion in diabetic patients. The challenge in most countries is not the science — it is the regulatory pathway. Getting stem cell therapy approved for routine clinical use in the US, UK, or EU takes 10–15 years and billions in trial funding.
China has solved this differently — not by bypassing safety, but by designating specific zones where approved-abroad or late-stage therapies can be offered to patients before completing the full domestic approval process.
Why Boao Lecheng — and Nowhere Else
Boao Lecheng International Medical Tourism Pilot Zone is a 20 km² special economic zone in Hainan Province, established in 2013 and governed by a unique set of healthcare regulations that exist nowhere else in mainland China.
Under the “Boao Nine Policies” framework, hospitals operating within the zone are permitted to:
- Use medical devices and drugs approved in the US, EU, Japan, or Australia — before those products receive NMPA (China FDA) approval
- Offer cellular therapies including stem cell treatments under supervised clinical protocols
- Admit international patients under expedited visa and medical visa arrangements
The stem cell diabetes program currently operating at Boao Lecheng is not available at any other location in mainland China. This is a direct result of the zone’s special regulatory status — the same therapy administered in Beijing or Shanghai would require full NMPA approval, which it does not yet have.
For international patients, this creates a specific opportunity: access to a supervised, clinically administered stem cell protocol that is legal, trackable, and backed by peer-reviewed research — at a fraction of the cost of equivalent programs in Switzerland or the United States.
Boao Lecheng is accessible via Haikou Meilan International Airport (HAK) or Sanya Phoenix International Airport (SYX), both of which receive direct international flights. The zone operates a dedicated international patient reception service, and most facilities employ English-speaking medical coordinators.
Who Qualifies for Treatment
Stem cell therapy for diabetes at Boao Lecheng is not suitable for every diabetic patient. Standard eligibility criteria applied by treating physicians typically include:
| Criterion | Details |
|---|---|
| Diagnosis | Type 2 diabetes (primary indication); some protocols accept Type 1 with residual beta-cell function |
| Duration | Diagnosed for at least 1 year; longer-duration cases may see more modest results |
| Age range | 18–70 years old (varies by protocol) |
| HbA1c level | Typically 7.5%–12% at time of enrollment |
| Current medications | Oral medications acceptable; insulin-dependent patients assessed case by case |
| Organ function | Normal or near-normal kidney and liver function required |
| Exclusions | Active cancer, severe cardiovascular disease, active infection, pregnancy |
Patients with diabetic complications — neuropathy, nephropathy, retinopathy — are not automatically excluded. Some treating centers have developed adjunct protocols specifically targeting these complications alongside the core metabolic treatment.
The most important step before booking is a pre-treatment medical review. China Care coordinates this as part of the intake process: your recent lab results, medical history, and current medications are reviewed by the treating team before any commitment is made.
What to Expect: The Treatment Process
The stem cell diabetes program at Boao Lecheng is typically delivered over 7–14 days, depending on the protocol and the patient’s clinical profile.
Step 1 — Pre-treatment workup (Days 1–2)
On arrival, patients undergo a comprehensive baseline assessment: fasting blood glucose, HbA1c, C-peptide levels, kidney and liver function panels, cardiac screening, and imaging as required. This establishes the baseline against which outcomes will be measured.
Step 2 — Stem cell preparation
Most programs use allogeneic umbilical cord-derived MSCs from a certified cell bank — meaning the cells are pre-prepared and do not require extraction from the patient. This eliminates the need for bone marrow harvest under general anaesthesia. The cells are expanded in a GMP-certified laboratory within the facility and quality-tested before administration.
Step 3 — Administration (Days 3–10)
Stem cells are administered via intravenous infusion, typically in 2–4 sessions spaced over several days. Each infusion takes 60–90 minutes and is performed under medical supervision with monitoring for adverse reactions. Some protocols include a targeted pancreatic infusion for patients with significant beta-cell depletion.
Step 4 — Observation and discharge
Following the final infusion, patients remain under observation for 24–48 hours. Discharge is followed by a detailed follow-up protocol including blood glucose monitoring, HbA1c testing at 1 month, 3 months, and 6 months, and direct communication with the treating team.
China Care provides a dedicated patient coordinator throughout the entire process — from pre-departure document preparation to in-facility translation, accommodation, and post-discharge follow-up coordination.
Results: What the Evidence Shows
The evidence base for MSC therapy in Type 2 diabetes has grown substantially over the past decade. Key findings from published research:
- A 2021 systematic review published in Stem Cell Reviews and Reports found that MSC infusion produced statistically significant reductions in HbA1c (average 1.2–2.1% reduction) and fasting blood glucose across multiple randomized trials
- A Phase II clinical trial conducted in China found that approximately 60% of treated patients reduced their diabetes medication dosage at 12-month follow-up, with 15–20% achieving insulin independence
- MSC therapy showed particularly strong results in patients with shorter disease duration (under 10 years) and preserved residual beta-cell function (detectable C-peptide)
It is important to be transparent about what the evidence does not yet show: long-term durability beyond 3–5 years is not yet established in large cohort studies. Some patients require a second treatment course. This is not a guaranteed cure — it is a clinically validated intervention with meaningful probability of significantly improving glycemic control and reducing medication dependence.
For patients who have spent years managing a progressive disease with an increasingly heavy medication burden, those are meaningful probabilities.
Cost Comparison: China vs. USA vs. Mexico
Stem cell therapy for diabetes exists in a global grey market. Pricing varies enormously by location, cell source, protocol quality, and regulatory oversight.
| Location | Estimated Cost | Regulatory Status | Notes |
|---|---|---|---|
| Boao Lecheng, China | $15,000–$35,000 USD | Supervised clinical protocol under special zone regulations | GMP-certified cells, physician oversight, tracked outcomes |
| United States | Not commercially available | FDA has not approved MSC therapy for diabetes | Some Phase III trials available — no cost but restricted eligibility |
| Switzerland / Germany | $40,000–$80,000 USD | Varies; some clinics operate under compassionate use | High cost; variable protocol quality |
| Mexico (Tijuana / Monterrey) | $8,000–$20,000 USD | Largely unregulated | No mandatory outcome tracking; variable cell quality |
| Thailand | $12,000–$25,000 USD | Semi-regulated; hospital-dependent | Some accredited centers; variable oversight |
The Boao Lecheng option sits at a specific intersection: better regulated than Mexico or Thailand, significantly cheaper than Europe, and clinically supervised in a way that unaccredited offshore clinics are not.
For patients considering medical tourism in China more broadly, the cost differential on advanced therapies is consistently 60–80% below Western equivalents.
How to Access Treatment as an International Patient
Step 1 — Initial inquiry
Contact China Care Health Tours with your basic medical history, current diabetes medications, and most recent HbA1c result. This takes 5 minutes and costs nothing.
Step 2 — Medical record review
We share your file with the Boao Lecheng treating team for eligibility assessment. You will receive a written response within 3–5 business days confirming eligibility and a preliminary treatment plan.
Step 3 — Visa and travel arrangement
China Care prepares your medical visa documentation — including the hospital invitation letter required for a medical visa application. Hainan also operates a 30-day visa-free entry policy for citizens of many countries, which some patients use instead of a formal medical visa.
Step 4 — Arrival and treatment
Our coordinator meets you on arrival in Hainan. All appointments, translations, and intra-facility logistics are managed by China Care throughout your stay.
Step 5 — Post-treatment follow-up
At 1, 3, and 6 months post-treatment, we coordinate follow-up lab work with the Boao team. You can have your blood drawn locally — results are shared with your treating physician in China for remote review and protocol adjustment if needed.
Frequently Asked Questions
Is stem cell therapy for diabetes legal in China?
Yes — within Boao Lecheng International Medical Tourism Pilot Zone. The zone operates under special regulations that permit supervised use of advanced therapies before full NMPA approval. Outside this zone, the same treatment would not be legally available at a clinical facility.
How long do the results last?
Published studies show maintained glycemic improvement in most patients for 12–36 months. Some patients require a second treatment course. Results are strongest in patients with shorter disease duration and preserved beta-cell function. Long-term durability beyond 5 years is not yet fully characterized in the literature.
Will I be able to stop taking insulin after treatment?
Some patients achieve insulin independence; others reduce dosage significantly. Outcomes vary by individual profile. Patients with Type 2 diabetes and residual beta-cell function show the most consistent results. Your treating physician will give a personalized probability estimate based on your clinical profile.
What are the risks?
MSC infusion is generally well-tolerated. The most commonly reported side effects are mild fever, fatigue, and transient flu-like symptoms in the 24–48 hours post-infusion. Serious adverse events are rare in published literature. All treatments at Boao Lecheng are conducted under physician supervision with emergency response capability.
Can I combine this with other treatments at Boao Lecheng?
Yes. Some patients use the trip to address multiple health concerns — for example, combining the diabetes stem cell protocol with an executive health screening or a consultation on other conditions. China Care can coordinate multi-treatment itineraries within the zone.
How much does a consultation cost?
The initial inquiry through China Care is free. A formal pre-treatment medical review by the Boao team is typically included in the treatment package or charged at a nominal fee that is deducted from treatment costs upon booking.
What if I am not eligible?
If the Boao team determines you are not a suitable candidate for stem cell therapy, China Care will advise on alternative treatment pathways — including conventional oncology and metabolic care at top Chinese hospitals.
Start Your Consultation
Stem cell therapy for diabetes is not available everywhere. Boao Lecheng is one of a small number of places in the world where it can be accessed legally, under clinical supervision, at a cost that makes it reachable for international patients.
The first step takes five minutes.
Learn More About Medical Tourism in China →
References
- Wikipedia. “Type 2 Diabetes.” Wikipedia, the Free Encyclopedia. https://en.wikipedia.org/wiki/Type_2_diabetes
- ClinicalTrials.gov. Search: “stem cell diabetes.” U.S. National Library of Medicine. https://clinicaltrials.gov/search?term=stem+cell+diabetes
- Multiple authors. “Mesenchymal Stem Cell Infusion in Type 2 Diabetes: Systematic Review.” Stem Cell Reviews and Reports, 2021. (Reported average HbA1c reduction of 1.2—2.1% across randomized trials.)
- Phase II clinical trial (China). MSC infusion in Type 2 diabetes; 60% of treated patients reduced diabetes medication at 12 months; 15—20% achieved insulin independence. (Referenced in article body.)
- National Medical Products Administration (NMPA). Regulatory framework for advanced therapies in China. https://www.nmpa.gov.cn/
- China Care Health Tours. “Cancer Treatment in China.” https://chinacarehealthtours.com/cancer-treatment-in-china/
- China Care Health Tours. “How to Get a Medical Visa for China: A Complete 2026 Guide.” https://chinacarehealthtours.com/how-to-get-a-medical-visa-for-china-a-complete-2026-guide/
